Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.

Roychoudhury S, Catrenich CE, McIntosh EJ, McKeever HD, Makin KM, Koenigs PM, Ledoussal B.

Antimicrob Agents Chemother. 2001 Apr;45(4):1115-20.

2.

Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.

Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55.

3.

Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.

Dubin DT, Fitzgibbon JE, Nahvi MD, John JF.

Antimicrob Agents Chemother. 1999 Jul;43(7):1631-7.

4.
5.

[In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].

Yagüe Guirao G, Martínez-Toldos MC, Alonso Manzanares MA, Gutiérrez Zufiaurre MN, Martínez-Andrés JA, Muñoz Bellido JL, García-Rodríguez JA, Segovia Hernández M.

Rev Esp Quimioter. 2000 Sep;13(3):271-5. Spanish.

PMID:
11086276
6.

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.

Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ.

Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7.

7.

Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.

Roychoudhury S, Twinem TL, Makin KM, McIntosh EJ, Ledoussal B, Catrenich CE.

J Antimicrob Chemother. 2001 Jul;48(1):29-36.

PMID:
11418510
9.
11.

Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

Takei M, Fukuda H, Kishii R, Hosaka M.

Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.

12.

Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations.

Roychoudhury S, Twinem TL, Makin KM, Nienaber MA, Li C, Morris TW, Ledoussal B, Catrenich CE.

Antimicrob Agents Chemother. 2001 Dec;45(12):3422-6.

13.

Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.

Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Köhrer K, Milatovic D.

FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):281-7.

14.
15.

Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Bogdanovich T, Esel D, Kelly LM, Bozdogan B, Credito K, Lin G, Smith K, Ednie LM, Hoellman DB, Appelbaum PC.

Antimicrob Agents Chemother. 2005 Aug;49(8):3325-33.

17.

In vitro activity of HSR-903, a new quinolone.

Takahashi Y, Masuda N, Otsuki M, Miki M, Nishino T.

Antimicrob Agents Chemother. 1997 Jun;41(6):1326-30.

18.

Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens.

Roychoudhury S, Ledoussal B.

Curr Drug Targets Infect Disord. 2002 Mar;2(1):51-65. Review.

PMID:
12462153
19.

Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.

Watanabe S, Ito T, Hiramatsu K.

J Antimicrob Chemother. 2007 Dec;60(6):1384-7. Epub 2007 Sep 21.

PMID:
17890283

Supplemental Content

Support Center